Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. (ALC) generates frequent news as a global eye care company listed on the SIX Swiss Exchange and the New York Stock Exchange. Company communications emphasize a long heritage in eye care, a broad Surgical and Vision Care portfolio, and a large international patient reach, which together make Alcon a regular subject of healthcare, medical device and capital markets coverage.
News about Alcon often highlights developments in its Surgical and Vision Care segments, including product launches and portfolio updates that address conditions such as cataracts, glaucoma, retinal diseases and refractive errors. The company has stated that it is advancing global launches of major products across these franchises, and such initiatives are typically announced through press releases and investor events.
Investors following ALC news can also expect updates on corporate strategy and transactions. For example, Alcon has reported on a definitive merger agreement with STAAR Surgical Company and later announced the termination of that agreement in a January 6, 2026 press release. These items appear in both company news and related regulatory filings, providing insight into how Alcon approaches acquisitions and refractive surgery strategy.
Coverage may further include Alcon’s participation in major healthcare conferences, where senior executives present the company’s outlook and discuss its Surgical and Vision Care businesses. Such events are typically accompanied by webcasts and formal announcements. By monitoring this news feed, readers can track key developments affecting Alcon’s product portfolio, strategic direction and presence in the global eye care market.
Yunqi Capital, a 5.1% shareholder of STAAR (NASDAQ: STAA), urged shareholders on December 17, 2025 to reject Alcon’s amended acquisition offer of $30.75 and back STAAR’s standalone trajectory.
Yunqi said proxy adviser Glass Lewis continues to oppose the merger while ISS flipped in favor but noted shareholders could reasonably remain opposed. Yunqi criticized STAAR’s go-shop process (company engaged with 21 third parties) and highlighted upcoming catalysts including a January 2026 launch of EVO ICL V5, which the firm says could carry a 30–70% premium to existing ICL pricing.
STAAR Surgical (NASDAQ:STAA) announced that independent analysts and proxy advisor ISS view the amended Alcon (SIX/NYSE:ALC) merger as providing value to STAAR stockholders. Under the revised agreement dated December 9, 2025, STAAR stockholders would receive $30.75 per share in cash, equal to a 74% premium to STAAR's 90-day VWAP as of August 4, 2025 and a 66% premium to the August 4 closing price.
Analysts cited a ~$1.6bn all-in valuation (~4.5x forward EV/Sales using blended 2026–2027 estimates of $271m and $300m) and noted limited competing bids after the go-shop. ISS updated its report to recommend shareholders vote FOR. A virtual Special Meeting is set for December 19, 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Broadwood Partners (owner of 30.2% of STAAR Surgical, NASDAQ: STAA) on Dec 9, 2025 responded to Alcon Inc.'s (NYSE: ALC) amended acquisition terms, urging shareholders to vote AGAINST the proposed sale. Broadwood says the board ran a flawed process, delayed votes three times, rejected other bidders, added a limited go‑shop, and accepted only a $150 million price bump (to $30.75 per share from $28). Broadwood highlights a $24 million CEO payout under original terms and asserts STAAR is worth substantially more as an independent company if management projections are met.
Alcon (SIX/NYSE: ALC) announced an amended merger agreement to acquire STAAR Surgical (NASDAQ: STAA) for $30.75 per share in cash, increasing the offer by roughly $150 million of equity value. The transaction represents an approximate $1.6 billion total equity value, a 74% premium to STAAR’s 90-day VWAP and a 66% premium to STAAR’s August 4, 2025 closing price.
Alcon said it will finance the deal with short- and long-term credit facilities, expects the merger to be accretive to earnings in year two, and anticipates closing in early 2026, subject to regulatory and STAAR stockholder approvals. STAAR stockholders are urged to vote ahead of a December 19, 2025 meeting.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Alcon (ALC)?
What is the market cap of Alcon (ALC)?
